NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
Search Tool Menu
NEWS: Envisia Genomic Classifier Highlighted in Updated Clinical Guidelines for IPF Diagnosis Learn More
Menu
Close Button
Decipher® Prostate Genomic Classifier
Providing clarity and confidence in treatment planning

The Decipher Prostate (Decipher Prostate Biopsy and Decipher Prostate RP) genomic classifier is a 22-gene, whole-transcriptome-developed test designed to help inform treatment decisions for men with localized prostate cancer at initial diagnosis and after surgical removal of the prostate. The test reports the Decipher Score, which prognosticates a patient's risk of metastasis within five years and provides risk estimates of prostate cancer-specific outcomes.

Decipher® Prostate Genomic Classifier
The Decipher Prostate Biopsy test is used for patients following a cancer diagnosis to inform whether the patient is a candidate for active surveillance, needs monotherapy or may benefit from multi-modality or intensified therapy. The Decipher Prostate RP test is used following surgery to guide decision-making regarding treatment timing and whether patients undergoing salvage radiotherapy may benefit from the addition of hormone therapy or may safely avoid hormone therapy and its side effects.

The Decipher Prostate genomic classifier is currently being investigated in seven National Cancer Institute-sponsored, phase 3, prospective, randomized controlled clinical trials; 13 phase 2/3 prospective trials; and more than 20 retrospective studies of phase 3 randomized controlled trials. Many of these trials require Decipher Prostate testing for study inclusion.

Decipher Prostate

Learn More About Decipher Prostate

Learn More